That's why it's difficult for long-term investors to justify investing in the company, especially given the many attractive ...

OpenAI has talked about how having an automated AI researcher was on its roadmap, and it’s shown the first glimpses of that ...

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Abstract: The Visualized LL parsing is presented, the algorithm is based on non-left recursive grammar, and in the environment of VC++, it is based on the relation matrix of the grammar, with the help ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Andrew Left is fighting a range of criminal and civil charges related to his trading practices, and other investors who make money by betting on a decline in stock prices are watching closely. By ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...